The entire NS5A coding region of a GT-1b Con1 replicon was replaced with cDNA of NS5A derived from six BL specimens of GT-1b-infected subjects14, 16 (Table 1A). HCV NS5A sequences derived from clinical specimens of GT-1b share a high degree of amino-acid identity with the GT-1b Con1 replicon (≥95.2%). As expected, even greater identity (≥98.9%) was observed between multiple clones derived from the same specimen (Table 1A). Special attention was given to the signature Temsirolimus supplier polymorphisms of each specimen to ensure
no cross-contamination among different specimens and/or replicons (data not shown). The replication-enhancing adaptive mutation, S2204I, in NS5A was introduced into all clones to enhance the ability for replicon replication. check details To obtain reliable EC50 values, hybrid replicons with a replication window (i.e., signal-to-noise ratio) ≥3 were used in transient replication assays (Table 1A). The Con1 replicon was used as a wild-type (WT) control for EC50 determination and also as a comparator for replication ability. Averaged EC50 and standard deviation (SD) values for multiple clones derived from each specimen are shown in Table 1B. NS3 protease and NS5B polymerase inhibitors were used as assay
controls. Previously characterized resistant substitutions were not identified by population sequencing in the BL specimens, except for subject T.14, 16 The EC50 values for BMS-790052 with clones derived from BL ranged from 0.001 to 0.003 nM, which is similar to WT (Con1) replicon (0.003 nM for BMS-790052; Table medchemexpress 1B). The specimen derived from subject T had ∼100% NS5A Q54H-Y93H substitutions at BL.16 The EC50 value for BMS-790052 on this variant was 0.050 nM, or ∼23-fold resistance to BMS-790052 (Table 1B).15, 16 The entire NS5A coding region of a GT-1a (H77c) replicon was replaced with cDNA of NS5A derived from 12 clinical specimens of 11 GT-1a-infected subjects.14, 16 Ten cDNAs were derived from BL specimens, one from a T4 specimen (4 hours after the first dosing), and one from a day 14 specimen (T312) (Table 2A) of subject P who received 60 mg of BMS-790052 once-daily as
monotherapy for 14 days.16 The replication-enhancing adaptive mutation, S2204I, in NS5A was introduced into all clones to enhance replicon replication. A total of 12 clones derived from subject E with a replication window (i.e., signal-to-noise ratio) less than 2 were not used for EC50 determinations. The amino-acid sequence identity between the NS5A consensus of each specimen and the GT-1a replicon, H77c, is ≥92.6%, and the identity between each clone and the consensus of the individual specimen is ≥93.3% (Table 2A). The EC50 values of BMS-790052 were determined with these GT-1a hybrid replicons (Table 2B). No previously characterized resistance substitutions were identified by population sequencing in the BL specimens. The averaged EC50 values ranged from 0.003 to 0.